In the version of this article initially published, the authors wrote, “we first treated BT474 human breast cancer cells with the clinically approved ATP-competitive tyrosine kinase inhibitor lapatinib and found that this resulted in the displacement of Cdc37 and Hsp90 from the target kinase ErbB2,” which implied that lapatinib promoted dissociation of ErbB2 from both Cdc37 and Hsp90, but the data for ErbB2 showed complete displacement of Cdc37 but not Hsp90. The error has been corrected in the HTML and PDF versions of the article.
Additional information
The online version of the original article can be found at 10.1038/nchembio.1212
Rights and permissions
About this article
Cite this article
Polier, S., Samant, R., Clarke, P. et al. Correction: Corrigendum: ATP-competitive inhibitors block protein kinase recruitment to the Hsp90-Cdc37 system. Nat Chem Biol 9, 406 (2013). https://doi.org/10.1038/nchembio0613-406d
Published:
Issue Date:
DOI: https://doi.org/10.1038/nchembio0613-406d
This article is cited by
-
Double duty
Nature Reviews Drug Discovery (2013)
